Cleave Bio
Cleave Biosciences is a biopharmaceutical company focused on developing novel therapeutics that target protein degradation pathways for challenging cancers. Their lead drug candidate, CB-5083, is a potent oral inhibitor of p97, a critical enzyme involved in protein homeostasis, currently undergoing Phase 1 clinical trials for multiple myeloma and advanced solid tumors.
The company's research emphasizes the role of AAA ATPases in cancer biology, aiming to identify new drug candidates that leverage a differentiated mechanism of action. With an extensive pipeline, Cleave Biosciences is dedicated to precision medicine approaches for patients with difficult-to-treat malignancies.
Generated from the website
Also at this address
You might also like
Partial Data by Foursquare.